QURE insider trading
NasdaqGS HealthcareuniQure N.V.: insider trade history from SEC Form 4 filings.
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Company website: www.uniqure.com
QURE insider activity at a glance
FilingIQ tracks 603 insider transactions for QURE in filings since Jun 7, 2017. The most recent transaction is dated Jul 2, 2026.
Across the full history, 0 open-market purchases
and 377 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on QURE insider trades is 63.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest QURE Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for QURE?
- FilingIQ tracks 603 Form 4 insider transactions for QURE (uniQure N.V.), covering filings from Jun 7, 2017 onwards. 0 of those are dated within the last 90 days.
- Are QURE insiders net buyers or net sellers?
- Across the full Form 4 history for QURE, 0 transactions (0%) were open-market purchases and 377 (63%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does QURE insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is QURE in?
- uniQure N.V. (QURE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.52B.
Methodology & sources
Every QURE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.